The St. Jude Comprehensive Cancer Center is dedicated to advancing research that addresses the unique challenges of pediatric cancers, the leading cause of disease-related death in children in the U.S. Since 55% of recurrent mutations in pediatric cancers are not found in adults, the "trickle down" of targeted therapies designed for adult cancers is ineffective. We focus on identifying and developing specific therapeutic targets to create effective treatments for pediatric cancers.
The SJCCC comprises 5 multidisciplinary research Programs that are organized with the specific intent of translating basic science discoveries into curative therapies for children with cancer, while minimizing long-term side effects: our Cancer Biology Program (CBP), which embeds basic cancer research within the heart of the SJCCC, facilitating direct interaction with the disease-oriented Programs and the major laboratory resources in the Center; our 3 disease-oriented Programs, focused on innovative translational and clinical research in Developmental Biology and Solid Tumors (DBSTP), Hematological Malignancies (HMP), and Neurobiology and Brain Tumors (NBTP); and our Cancer Control and Survivorship Program (CCSP), which strives to translate discoveries into effective strategies to avert or mitigate treatment-related complications and improve the quality of life for survivors of pediatric cancer.
At St. Jude, we are proud to host a network of Centers of Excellence, each dedicated to pushing the boundaries of scientific discovery in key fields. Read more.
St. Jude's blue sky process allows us to identify emerging opportunities and pursue them, while guided by a plan that outlines bold strategies for the future.
